INBX Stock Overview
A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Inhibrx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.11 |
| 52 Week High | US$39.79 |
| 52 Week Low | US$14.31 |
| Beta | 2.88 |
| 11 Month Change | -0.55% |
| 3 Month Change | -6.42% |
| 1 Year Change | 38.66% |
| 33 Year Change | 55.97% |
| 5 Year Change | n/a |
| Change since IPO | 65.34% |
Recent News & Updates
Recent updates
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Jun 07Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?
May 13
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23Shareholder Returns
| INBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.09% | 2.1% | -0.5% |
| 1Y | 38.7% | 12.0% | 24.2% |
Return vs Industry: INBX exceeded the US Biotechs industry which returned 4.6% over the past year.
Return vs Market: INBX exceeded the US Market which returned 25.2% over the past year.
Price Volatility
| INBX volatility | |
|---|---|
| INBX Average Weekly Movement | 1.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: INBX has not had significant price volatility in the past 3 months.
Volatility Over Time: INBX's weekly volatility has decreased from 8% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 169 | Mark Lappe | inhibrx.com |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
| INBX fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | -US$271.15m |
| Revenue (TTM) | US$1.78m |
1,002x
P/S Ratio-6.6x
P/E RatioIs INBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX income statement (TTM) | |
|---|---|
| Revenue | US$1.78m |
| Cost of Revenue | US$218.11m |
| Gross Profit | -US$216.32m |
| Other Expenses | US$54.83m |
| Earnings | -US$271.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.17 |
| Gross Margin | -12,132.47% |
| Net Profit Margin | -15,207.80% |
| Debt/Equity Ratio | 1,799.9% |
How did INBX perform over the long term?
See historical performance and comparison